ArticleEpilepsia2026
CaMKIIβ insufficiency disrupts cortical networks, producing aberrant low-gamma oscillations and seizure susceptibility.
Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivePathogenic variants in the calcium/calmodulin-dependent protein kinase II B gene (CAMK2B) have been associated with neurodevelopmental disorders, including epilepsy, yet the mechanisms underlying cortical dysfunction remain largely unclear. Building on our previous clinical report of a patient carrying the CaMKIIβ P213L variant and our prior characterization of the corresponding mouse models, we investigated how P213L-associated CaMKIIβ insufficiency alters cortical network dynamics and susceptibility to pentylenetetrazol (PTZ)-induced seizures in vivo.
methodsWe performed electroencephalographic recordings for CaMKIIβ P213L knock-in mice under baseline and pharmacological modulation. Susceptibility to seizure induction by the chemoconvulsant PTZ was assessed. Cortical CaMKIIβ expression and Thr287 phosphorylation levels were quantified and compared to those in CaMKIIβ knockout mice.
resultsHeterozygous and homozygous knock-in mice exhibited aberrant low-gamma (20-50 Hz) oscillations during resting state with behavioral immobility. These aberrant low-gamma oscillations were sensitive to γ-aminobutyric acid (GABA)-ergic modulation: pentylenetetrazol (PTZ) induced a downward shift in the gamma-band peak frequency, whereas isoflurane, diazepam, and valproic acid suppressed the aberrant low-gamma oscillations. PTZ administration increased seizure severity in both heterozygous and homozygous knock-in mice, but lethality occurred only in homozygous mice. We quantified cortical CaMKIIβ expression and Thr287 phosphorylation, both of which were reduced in knock-in mice. Knockout mice recapitulated the aberrant low-gamma oscillations and their pharmacological modulation observed in knock-in mice, supporting the role of CaMKIIβ insufficiency in driving the phenotype. SIGNIFICANCE: These findings suggest that CaMKIIβ insufficiency disrupts cortical excitatory-inhibitory balance, leading to the aberrant low-gamma oscillations and increased seizure susceptibility. Our findings establish a mechanistic link between CaMKIIβ deficiency and epilepsy-related phenotypes in neurodevelopmental disorders. The P213L variant represents a loss-of-function variant with reduced CaMKIIβ expression and phosphorylation, and provides a valuable model for investigating disease mechanisms and developing potential therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.